Holen Sie sich die Stockscreener-App
6.40
2.29%
-0.15
Schlusskurs vom Vortag:
$6.55
Offen:
$6.37
24-Stunden-Volumen:
47,909
Relative Volume:
0.27
Marktkapitalisierung:
$365.04M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-66.86M
KGV:
-5.3333
EPS:
-1.2
Netto-Cashflow:
$-58.82M
1W Leistung:
-4.19%
1M Leistung:
+4.75%
6M Leistung:
+37.63%
1J Leistung:
+20.30%
1-Tages-Spanne:
$6.31
$6.635
1-Wochen-Bereich:
$6.25
$6.77
52-Wochen-Spanne:
$2.60
$7.77
Design Therapeutics Inc Stock (DSGN) Company Profile
Firmenname
Design Therapeutics Inc
Sektor
Branche
Telefon
858-293-4900
Adresse
6005 HIDDEN VALLEY ROAD, CARLSBAD
Vergleichen Sie DSGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
6.41 | 373.01M | 0 | -66.86M | -58.82M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.10 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
629.34 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.65 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
836.79 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.68 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-05-04 | Hochstufung | Goldman | Sell → Neutral |
| 2022-06-10 | Eingeleitet | Wedbush | Outperform |
| 2022-05-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-01-19 | Eingeleitet | Goldman | Sell |
| 2021-04-20 | Eingeleitet | Goldman | Neutral |
| 2021-04-20 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Design Therapeutics Inc Aktie (DSGN) Neueste Nachrichten
Regression analysis insights on Design Therapeutics Inc. performance2025 Year in Review & Short-Term Trading Opportunity Alerts - newser.com
How high can Design Therapeutics Inc. stock goJuly 2025 Market Mood & Low Risk High Reward Trade Ideas - newser.com
Analyzing Design Therapeutics Inc. with risk reward ratio chartsJuly 2025 Update & AI Forecasted Entry/Exit Points - newser.com
Why retail investors favor Design Therapeutics Inc. stockStock Surge & Safe Swing Trade Setups - newser.com
What indicators show strength in Design Therapeutics Inc.Market Growth Summary & Real-Time Sentiment Analysis - newser.com
How to integrate Design Therapeutics Inc. into portfolio analysis toolsEarnings Overview Report & Comprehensive Market Scan Insights - newser.com
Technical signs of recovery in Design Therapeutics Inc.2025 Market Overview & Accurate Buy Signal Alerts - newser.com
Design Therapeutics Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Is Design Therapeutics Inc. stock poised for growthTrade Entry Summary & Verified Short-Term Trading Plans - newser.com
How to interpret RSI for Design Therapeutics Inc. stockJuly 2025 Outlook & Weekly Return Optimization Alerts - newser.com
Developing predictive dashboards with Design Therapeutics Inc. dataPortfolio Growth Summary & Weekly Top Gainers Alerts - newser.com
Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
How to recover losses in Design Therapeutics Inc. stockWeekly Trade Report & Weekly Sector Rotation Insights - newser.com
Design Therapeutics, Inc. (NASDAQ:DSGN) Short Interest Update - MarketBeat
What recovery options are there for Design Therapeutics Inc.July 2025 Review & Free Technical Pattern Based Buy Signals - newser.com
Design Therapeutics (DSGN) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Should you wait for a breakout in Design Therapeutics Inc.Market Risk Summary & Safe Capital Growth Trade Ideas - newser.com
Published on: 2025-10-31 05:37:27 - newser.com
Published on: 2025-10-31 00:22:12 - newser.com
Published on: 2025-10-31 00:00:29 - newser.com
Published on: 2025-10-29 02:11:27 - newser.com
Forecasting Design Therapeutics Inc. price range with options data2025 Top Gainers & Daily Chart Pattern Signal Reports - newser.com
How buybacks impact Design Therapeutics Inc. stock valueJuly 2025 Highlights & Entry and Exit Point Strategies - fcp.pa.gov.br
Design Therapeutics Advances DT-168 Study for Fuchs Dystrophy - TipRanks
Design Therapeutics Advances DT-216P2 Study for Friedreich’s Ataxia - TipRanks
Design Therapeutics Advances with New Study on DT-216P2 for Friedreich Ataxia - TipRanks
Finanzdaten der Design Therapeutics Inc-Aktie (DSGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.19%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):